Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Formoterol Fumarate in the Pressair DPI, Low Dose
Formoterol in the Pressair DPI, Low Dose · 1 trial · 1 indication
AUC0-6 is area under the curve from time 0 to 6 hours Serial spirometry was performed at -60 min predose, at 5 (+5) and 30 (±5) min post-dose, and at 1, 2, 3, 4, and 6 hrs post-dose (±15 min) Change from baseline was baseline of each treatment period The normalized FEV1 AUC0-6 was calculated by means of the trapezoidal method, dividing the area under the curve by the corresponding time intervals
| Arm | Type | Description |
|---|---|---|
| Experimental 1 | EXPERIMENTAL | Formoterol Fumarate in the Pressair Pressair Dry Powder Inhaler (DPI), Low Dose |
| Experimental 2 | EXPERIMENTAL | Formoterol fumarate in the Pressair Dry Powder Inhaler (DPI), High Dose |
| Active Comparator 1 | ACTIVE_COMPARATOR | Foradil Aerolizer, Low Dose |
| Active Comparator 2 | ACTIVE_COMPARATOR | Foradil Aerolizer, High Dose |
| Placebo | PLACEBO_COMPARATOR | Dose matched placebo |
| Name | Type | Description |
|---|---|---|
| Formoterol Fumarate in the Pressair DPI, Low Dose | DRUG | Formoterol Fumarate in the Pressair DPI 6 micrograms, twice a day for 14 days |
| Formoterol Fumarate in the Pressair DPI, High Dose | DRUG | Formoterol Fumarate in the Pressair DPI 12 micrograms, twice a day for 14 days |
| Foradil Aerolizer, Low Dose | DRUG | Foradil Aerolizer 12 micrograms, twice a day for 14 days |
| Foradil Aerolizer, High Dose | DRUG | Foradil Aerolizer 24 micrograms, twice per day for 14 days |
| Placebo | DRUG | Placebo in the Pressair for 14 days |
Inclusions: * Patients with mild-to-moderate asthma for at least 6 months prior to Visit 1 (as defined in the GINA Guidelines) which is unlikely to exacerbate during the study (e.g., due to seasonal allergen exposure). * Patients must be on a stable dose of Inhaled Corticosteroids (ICS) for at leas...
Top 15 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 5 | PHASE3 | Trelegy Ellipta, Depemokimab, GSK5784283, Ventolin |
| Sanofi SA Sponsored ADR | SNY | 7 | PHASE3 | Dupilumab, Amlitelimab, Lunsekimig |
| AstraZeneca PLC | AZN | 26 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07275315 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Formoterol in the Pressair DPI, low dose is an investigational small molecule therapy being developed by AstraZeneca PLC for asthma. It delivers a low dose of formoterol fumarate through the Pressair dry powder inhaler. It is in Phase 2 clinical development and is not approved for commercial use.
Formoterol in the Pressair DPI, low dose is being studied for the treatment of asthma in adults. The Phase 2 program enrolled patients aged 18 years and older with mild to moderate asthma. The drug remains investigational and has not been approved for any indication.
Formoterol in the Pressair DPI, low dose targets ADRB2, the beta-2 adrenergic receptor. It acts as an agonist at this receptor. This is the same receptor class targeted by other long-acting beta-2 agonist bronchodilators used in respiratory medicine.
AstraZeneca PLC, which trades under the ticker AZN, is the developer of formoterol in the Pressair DPI, low dose. The company is responsible for the clinical development program evaluating this low-dose formoterol fumarate formulation delivered via the Pressair dry powder inhaler.
Formoterol in the Pressair DPI, low dose is in Phase 2 clinical development. The single completed trial was a Phase 2 study. The drug is investigational and has not received FDA approval. No active trials are currently listed for this asset.
Formoterol in the Pressair DPI, low dose was evaluated in NCT01641081, a completed Phase 2 study comparing formoterol fumarate in the Pressair DPI to the Foradil Aerolizer in patients with mild to moderate asthma. The trial enrolled 174 participants in the United States and was randomized, double-blind, and placebo-controlled.
Yes. Formoterol in the Pressair DPI, low dose is also known as formoterol fumarate in the Pressair DPI, low dose. Both names refer to the same AstraZeneca Phase 2 asthma asset, a low-dose formoterol fumarate formulation delivered through the Pressair dry powder inhaler.